Tandem Diabetes Care, Inc. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO John F. Sheridan; PEO total compensation $6.86M; PEO compensation actually paid $2.92M; Other NEO average total compensation $1.97M.
- 2024-12-31: PEO total compensation $8.53M; PEO compensation actually paid $6.79M; Other NEO average total compensation $1.95M.
- 2023-12-31: PEO total compensation $4.65M; PEO compensation actually paid $1.51M; Other NEO average total compensation $1.50M.
- 2022-12-31: PEO total compensation $6.38M; PEO compensation actually paid -$8.34M; Other NEO average total compensation $1.75M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | John F. Sheridan | $6.86M | $2.92M | $1.97M | $1.58M | $22.97 | $99.39 | -$204.70M | Sales $1.01B | 2026-04-07 |
| 2024-12-31 | $8.53M | $6.79M | $1.95M | $1.75M | $60.43 | $105.42 | -$96.00M | $940.20M | 2026-04-07 | |
| 2023-12-31 | $4.65M | $1.51M | $1.50M | $1.09M | $49.62 | $106.34 | -$222.60M | $747.70M | 2026-04-07 | |
| 2022-12-31 | $6.38M | -$8.34M | $1.75M | -$3.18M | $75.41 | $99.81 | -$94.60M | $801.20M | 2026-04-07 | |
| 2021-12-31 | $5.74M | $16.41M | $1.62M | $5.06M | $252.51 | $125.43 | $15.60M | $702.80M | 2026-04-07 | |
| 2024-12-31 | John F. Sheridan | $8.53M | $6.79M | $1.95M | $1.75M | $60.43 | $105.42 | -$96.00M | Sales $940.20M | 2025-04-08 |
| 2023-12-31 | $4.65M | $1.51M | $1.50M | $1.09M | $49.62 | $106.34 | -$222.60M | $747.70M | 2025-04-08 | |
| 2022-12-31 | $6.38M | -$8.34M | $1.75M | -$3.18M | $75.41 | $99.81 | -$94.60M | $801.20M | 2025-04-08 | |
| 2021-12-31 | $5.74M | $16.41M | $1.62M | $5.06M | $252.51 | $125.43 | $15.60M | $702.80M | 2025-04-08 | |
| 2020-12-31 | $3.79M | $11.40M | $1.96M | $6.03M | $160.51 | $130.04 | -$34.40M | $498.80M | 2025-04-08 | |
| 2023-12-31 | $4.65M | $1.51M | $1.50M | $1.09M | $49.62 | $106.34 | -$222.60M | $747.70M | 2024-04-09 | |
| 2022-12-31 | $6.38M | -$8.34M | $1.75M | -$3.18M | $75.41 | $99.81 | -$94.60M | $801.20M | 2024-04-09 | |
| 2021-12-31 | $5.74M | $16.41M | $1.62M | $5.06M | $252.51 | $125.43 | $15.60M | $702.80M | 2024-04-09 | |
| 2022-12-31 | John F. Sheridan | $6.38M | -$8.34M | $1.75M | -$3.18M | $75.00 | $119.00 | -$94.60M | worldwide sales $801.20M | 2023-04-12 |
| 2021-12-31 | $5.74M | $16.41M | $1.62M | $5.06M | $253.00 | $147.00 | $15.60M | $702.80M | 2023-04-12 | |
| 2020-12-31 | $3.79M | $11.40M | $1.96M | $6.03M | $161.00 | $117.00 | -$34.40M | $498.80M | 2023-04-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |